Latest News

A recent study reveals dual orexin receptor agonists (DORAs) show significantly lower abuse potential compared to traditional insomnia medications.

Teva's emrusolmin receives FDA fast track designation as a potential breakthrough treatment for multiple system atrophy, targeting neurodegeneration.

At 48 weeks, patients treated with blarcamesine showed an 84.7% reduction in decline on the primary cognitive end point compared with placebo.

The VP of clinical development at Alkermes detailed phase 2 results for alixorexton, an oral, selective orexin 2 receptor agonist, in narcolepsy type 1, including benefits for fatigue, cognition, and weakness.

Catch up on any of the neurology news headlines you may have missed in August 2025, compiled into 1 place by the NeurologyLive® team.

Phase 3 trial results reveal EPX-100's safety and tolerability in Dravet syndrome, supporting its potential as an effective adjunctive therapy.

Patients treated with RAP-219 had a 77.8% reduction in clinical seizures, with 24% achieving seizure freedom over 8 weeks, potentially supporting the agent’s advancement to phase 3 trials.

A recent trial shows that 3 infusions of stem cells significantly enhance motor function in Parkinson patients, highlighting the need for further research.

New findings presented at the 2025 International Epilepsy Conference indicated that cenobamate may provide benefits beyond seizure control in patients with uncontrolled focal-onset seizures.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on RNA therapeutics for neuromuscular disorders.

AL-S Pharma's AP-101 shows promising safety and efficacy in ALS patients, paving the way for future treatments targeting misfolded SOD1 proteins.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 5, 2025.